27T51
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for 27T51, covering 2026-02-03 to 2026-02-03. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers [Phase 1]